Kimberly Manhard
2018
In 2018, Kimberly Manhard earned a total compensation of $2.4M as Executive Vice President, Drug Development at Heron Therapeutics, a 26% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $350,097 |
|---|---|
| Option Awards | $1,605,220 |
| Salary | $466,796 |
| Other | $8,250 |
| Total | $2,430,363 |
Manhard received $1.6M in option awards, accounting for 66% of the total pay in 2018.
Manhard also received $350.1K in non-equity incentive plan, $466.8K in salary and $8.3K in other compensation.
Rankings
In 2018, Kimberly Manhard's compensation ranked 4,783rd out of 14,244 executives tracked by ExecPay. In other words, Manhard earned more than 66.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,783 out of 14,244 | 66th |
Division Manufacturing | 1,795 out of 5,759 | 69th |
Major group Chemicals And Allied Products | 651 out of 2,122 | 69th |
Industry group Drugs | 548 out of 1,811 | 70th |
Industry Pharmaceutical Preparations | 423 out of 1,385 | 70th |
Source: SEC filing on April 23, 2020.
Manhard's colleagues
We found three more compensation records of executives who worked with Kimberly Manhard at Heron Therapeutics in 2018.
News
Heron Therapeutics Executive Vice President, Drug Development Kimberly Manhard's 2022 pay falls 22% to $1.4M
May 1, 2023
Heron Therapeutics CEO Barry Quart's 2021 pay rises 2% to $5.4M
April 25, 2022
Heron Therapeutics CEO Barry Quart's 2020 pay slips 9% to $5.3M
April 22, 2021
Heron Therapeutics CEO Barry Quart's 2019 pay slips 2% to $5.9M
April 23, 2020